Vyleesi (Bremelanotide) in Girls Under 12: School, Activity, and Safety Considerations

Why This Question Exists and Why the Answer Is Unambiguous

Parents, caregivers, and sometimes clinicians search for pediatric drug information across every approved medication, including ones that have absolutely no pediatric application. Bremelanotide is one of those drugs. The short answer is that bremelanotide should never be given to a girl under 12, or to any child, because the drug has no approved pediatric indication, no published pediatric pharmacokinetic data, and no safety data in prepubertal females.

Understanding why this boundary exists, and what the drug actually does in the adult female body, helps parents ask better questions and helps clinicians redirect conversations appropriately.

What Bremelanotide (Vyleesi) Actually Is

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist. It works primarily at melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the central nervous system. The FDA approved bremelanotide in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) accompanied by marked distress or interpersonal difficulty.

HSDD is an adult condition. It is defined by a persistent or recurrent deficiency of sexual desire that causes clinically meaningful distress. It has no clinical meaning in prepubertal girls, whose hypothalamic-pituitary-gonadal (HPG) axis is quiescent. The condition the drug treats simply does not exist in children under 12.

How It Works in the Adult Female Brain

In adult premenopausal women, sexual desire involves a balance of excitatory pathways (dopaminergic, melanocortinergic) and inhibitory pathways (opioidergic, serotoninergic). Bremelanotide activates MC3R and MC4R in regions including the hypothalamus and limbic system, modulating this excitatory-inhibitory balance. A 2019 phase 3 trial published in JAMA (RECONNECT trial) showed bremelanotide produced a statistically significant increase in satisfying sexual events and a reduction in distress about low desire compared with placebo in adult premenopausal women.

That same central receptor system, in a girl under 12, plays entirely different roles. MC3R and MC4R are involved in energy homeostasis, adrenal function, and the regulation of puberty onset. Artificially stimulating these receptors in a prepubertal child could theoretically disrupt pubertal timing, adrenal function, and appetite regulation. No human data exists on this risk because no ethical trial has ever enrolled prepubertal children in bremelanotide studies, and none ever should.

The Adult-Only Clinical Trial Record

Every clinical trial supporting bremelanotide's approval enrolled adult women. The RECONNECT studies enrolled women aged 21 through 57 with confirmed HSDD diagnosed using validated instruments including the Decreased Sexual Desire Screener (DSDS). The lower age bound of 21 was chosen specifically because the studies required an established sexual baseline, reproductive-age hormonal status, and a stable relationship context for comparison. There is no clinical trial data below age 21, and the FDA label carries no pediatric section beyond a statement that safety and efficacy in pediatric patients have not been established.

School and Activity Considerations: Why This Section Cannot Apply to Girls Under 12

A structured framework for understanding why "school and activity considerations" is a non-applicable category for pediatric bremelanotide use:

Category 1: Approved indication absent. Bremelanotide treats HSDD. HSDD requires an established desire baseline, adult hormonal status, and clinically meaningful personal distress about low sexual desire. None of these criteria apply to a prepubertal girl.

Category 2: Dosing unknown. The approved adult dose is 1.75 mg administered subcutaneously approximately 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than once per week. Per the FDA prescribing information, no pediatric dose has been studied or established. There is no basis for any dose calculation in a child.

Category 3: Pharmacokinetics differ across life stages. In adult women, bremelanotide reaches peak plasma concentration approximately 1 hour after subcutaneous injection, with a half-life of approximately 2.7 hours. Body weight, fat distribution, and hepatic metabolism differ substantially between prepubertal children and adult women. Pediatric pharmacokinetic modeling for bremelanotide does not exist in the published literature.

Category 4: Side effect profile not characterized in children. In adult clinical trials, the most common adverse effects were nausea (occurring in approximately 40% of women), flushing (approximately 20%), and injection site reactions. Transient blood pressure increases averaging 6 mmHg systolic were observed after each dose, resolving within 12 hours. Cardiovascular effects in growing children with different baseline hemodynamics are completely unstudied.

Category 5: No regulatory pathway exists. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations where there is a plausible pediatric use. Bremelanotide has no plausible pediatric use, so no pediatric study requirement was imposed. This is not a gap waiting to be filled. It is the correct regulatory outcome.

Because none of the five categories above have any pediatric applicability, questions about whether a girl under 12 can take bremelanotide at school, before sports practice, or during any structured activity have no clinically meaningful answer. The drug must not be administered to a child, full stop.

What Parents and Caregivers Should Know If This Drug Appeared in Their Child's Life

There are scenarios in which a parent might encounter bremelanotide in relation to a child, none of them appropriate clinical use:

• A prescription written in error
• A child accessing a parent's medication
• A caregiver or third party administering it without medical oversight
• Confusion with another peptide or medication

If a child under 12 has been exposed to bremelanotide, contact Poison Control at 1-800-222-1222 immediately, bring the medication packaging, and seek emergency evaluation. Watch for nausea, vomiting, flushing, blood pressure changes, and altered level of consciousness.

Safe Storage Is a Clinical Obligation

Bremelanotide is dispensed as a prefilled autoinjector. Adult women prescribed this medication must store it out of reach of all children, ideally in a locked medication storage container. The FDA prescribing information provides no explicit pediatric accidental exposure guidance because the expectation is that safe storage prevents exposure entirely.

The Correct Clinical Context: Who Bremelanotide Is Actually For

Bremelanotide is indicated for a very specific adult population. Understanding who it is appropriate for clarifies why its boundaries are so clearly drawn.

Appropriate Candidates: Premenopausal Women With HSDD

A woman is a reasonable candidate for bremelanotide if she:

• Is premenopausal, with an intact HPG axis
• Has a diagnosis of acquired, generalized HSDD confirmed by a clinician
• Experiences marked personal distress about low desire (not just a partner's concern)
• Has had other contributing causes addressed, including depression, relationship conflict, hormonal contraceptive effects on libido, thyroid dysfunction, and medication side effects
• Has no cardiovascular disease history, as the drug causes transient blood pressure elevation
• Is using reliable contraception if sexually active and not pursuing pregnancy (see pregnancy section below)

ACOG Committee Opinion guidance on sexual dysfunction emphasizes a biopsychosocial evaluation before initiating pharmacotherapy for HSDD, meaning bremelanotide is rarely, if ever, a first-line intervention.

Who Should Not Use Bremelanotide

Beyond children under 12, bremelanotide is contraindicated or not recommended in:

• Postmenopausal women (no approval or efficacy data; HSDD in this population may have different hormonal underpinnings)
• Women with known cardiovascular disease or uncontrolled hypertension
• Women who are pregnant or planning pregnancy
• Women breastfeeding (unknown lactation safety)
• Women taking naltrexone or other opioid antagonists, due to potential interaction
• Women whose low desire is fully explained by a treatable underlying condition not yet addressed

Sex-Specific Physiology Across Life Stages

Reproductive Years (Approximately Ages 15 to 45)

In women of reproductive age with an intact menstrual cycle, sexual desire naturally varies across the cycle. Research shows desire peaks in the late follicular phase around ovulation, corresponding to rising estradiol and luteinizing hormone. Bremelanotide does not interact with this cycle, but its clinical trials were conducted in women who were not on hormonal contraception or had stable hormonal status, so its effectiveness relative to cycle phase is not well characterized.

Perimenopause

Perimenopausal women experience hormonal fluctuation that can suppress desire independently of HSDD. Bremelanotide is not approved for perimenopausal women whose primary issue is estrogen or androgen decline. These women may benefit more from testosterone therapy (off-label) or addressing genitourinary syndrome of menopause (GSM). Bremelanotide should not be initiated as a substitute for hormonal assessment in perimenopause.

Postmenopause

The FDA approval explicitly covers premenopausal women only. The RECONNECT trial did not enroll postmenopausal women. Extrapolating efficacy to postmenopausal women is not supported by the clinical data.

Trying to Conceive (TTC)

Women actively trying to conceive should not use bremelanotide. The drug is contraindicated in pregnancy, and its effects at the time of conception and early implantation have not been studied. Stopping bremelanotide before trying to conceive is the appropriate clinical step.

Prepubertal Girls (<12)

The HPG axis is dormant in prepubertal girls. Gonadotropin-releasing hormone (GnRH) pulse frequency is suppressed, estradiol is at prepubertal levels, and the central circuitry governing adult sexual function is not yet active in the same way. There is no physiological rationale, no clinical indication, and no safety data supporting any use of bremelanotide in this age group. This is the most important life-stage boundary for this drug.

Pregnancy, Lactation, and Contraception: Required Safety Section

This section is required for every drug article at WomanRx, and for bremelanotide, the pregnancy considerations carry serious weight.

Pregnancy: Contraindicated

The FDA prescribing information for bremelanotide classifies it as contraindicated in pregnancy. Animal reproduction studies showed that bremelanotide caused fetal harm at doses approximating human exposure. Specifically, in rat studies, embryofetal death occurred at doses 0.8 times the maximum recommended human dose based on AUC comparison. Darkened (melanized) fetal fur in animals was also observed, consistent with MC1R activity in melanocytes.

There is no adequate and well-controlled human pregnancy data. The mechanistic concern is real: melanocortin receptors are expressed in placental tissue and in fetal development. Any woman who becomes pregnant while using bremelanotide should discontinue it immediately and contact her obstetric provider.

Contraception Requirement

Any woman of reproductive age using bremelanotide must use effective contraception. This is not a soft recommendation. Given the animal fetal harm data and the absence of human safety data in pregnancy, unintended pregnancy while using this drug carries unknown but potentially meaningful risk to the fetus.

Effective contraceptive options while using bremelanotide include long-acting reversible contraceptives (copper IUD, levonorgestrel IUD), combined oral contraceptives, contraceptive patch or ring, progestin-only pill, or barrier methods used consistently. Note that hormonal contraceptives themselves may suppress desire in some women, which creates a clinical tension worth discussing with your provider before starting bremelanotide.

Lactation: Unknown Transfer, Avoid Use

There are no human studies measuring bremelanotide transfer into breast milk. The drug is a peptide and may be partially degraded in the infant gut if transferred, but the degree of transfer and any infant exposure are unknown. Per the FDA label, the manufacturer advises that women should not breastfeed while using bremelanotide. Given the absence of safety data, this is the appropriate conservative position.

Women in the postpartum period experiencing low desire should discuss the full context, including hormonal status, sleep deprivation, breastfeeding-related estrogen suppression, and relationship factors, with their provider before attributing the issue to HSDD. Postpartum low desire is extremely common and rarely requires pharmacotherapy.

Evidence Gaps and What Is Extrapolated vs. Directly Studied

Women have historically been underrepresented in clinical trials across medicine, though bremelanotide is unusual in that it was studied exclusively in women. The evidence gaps here are different in character.

What is directly studied:

• Efficacy in premenopausal women aged 21 to 57 with confirmed HSDD (RECONNECT trials)
• Safety and adverse event profile in this adult population
• Pharmacokinetics in adult women at the approved 1.75 mg dose
• Animal reproductive toxicity

What is extrapolated or unknown:

• Efficacy and safety in women under 21
• Efficacy and safety in perimenopausal women with mixed hormonal and desire concerns
• Efficacy and safety in postmenopausal women
• Any pediatric pharmacokinetics or safety
• Long-term cardiovascular effects of repeated transient blood pressure elevation
• Effects in women with PCOS, whose hormonal profiles differ substantially from the trial population
• Interaction with hormonal contraceptives on both efficacy and desire outcomes

The Menopause Society (formerly NAMS) acknowledges that evidence-based treatment options for HSDD in postmenopausal women remain limited, partly because bremelanotide was never studied in that group. This is an honest representation of where the science currently stands.

Conditions the Drug Touches: A Women&apos;s Health Context

Bremelanotide intersects with several female-specific conditions beyond HSDD itself.

PCOS. Women with polycystic ovary syndrome (PCOS) often experience disruptions in sexual function related to hyperandrogenism, body image concerns, depression, and insulin resistance. HSDD can co-occur with PCOS. Bremelanotide has not been studied in women with PCOS as a distinct population, and PCOS-related hormonal differences may affect both efficacy and side effect profile.

Hormonal acne and contraception. Some women use combined oral contraceptives partly for acne management. These same contraceptives may suppress desire, creating a cycle where the treatment for one female condition (acne) contributes to another (low desire). Bremelanotide does not address this hormonal root cause.

Postpartum depression and low desire. Postpartum depression is associated with low sexual desire, but it is not the same as HSDD and should be treated with appropriate mental health and hormonal support before pharmacotherapy for desire is considered.

Female pattern hair loss. MC1R activity affects pigmentation, and bremelanotide's melanocortin agonism has produced transient hyperpigmentation (darkening of the face, gums, and breasts) in some adult trial participants. This is not a hair loss treatment and should not be confused with one.

Thyroid dysfunction. Hypothyroidism is associated with low libido in women and must be ruled out before attributing low desire to HSDD. Thyroid-stimulating hormone (TSH) should be checked as part of any HSDD workup.

What to Tell Your Daughter&apos;s School, Coach, or Pediatrician

If you are a parent reading this because bremelanotide came up in a conversation about your daughter, here is what matters most.

No pediatrician, school nurse, coach, or other adult should ever administer or recommend bremelanotide to a girl under 12. If you have received such a suggestion, seek a second opinion from a board-certified pediatric endocrinologist. The drug has no pediatric indication, no pediatric dose, no pediatric safety data, and no school or activity context that makes it appropriate.

If your daughter is experiencing a concern that led someone to suggest this drug, the real question is what that underlying concern actually is. Prepubertal girls do not experience HSDD. Concerns about puberty timing, sexual development, hormonal function, or behavioral changes in girls under 12 belong in the hands of a pediatric endocrinologist or adolescent medicine specialist, not in a conversation about a drug approved for adult sexual dysfunction.

As WomanRx reviewer Dr. Elena Vasquez, MD notes: "The only correct pediatric consideration for bremelanotide is ensuring it is stored safely away from children. There is no dose, no indication, no clinical scenario in which a girl under 12 should receive this medication. Any question framed otherwise reflects a fundamental misunderstanding of the drug's mechanism and the condition it treats."

Quick Reference: Bremelanotide by Life Stage

| Life Stage | Appropriate Use | Notes | |---|---|---| | Prepubertal (<12) | Never | No indication, no data, contraindicated | | Adolescent (12-20) | No | Not approved; no trial data under 21 | | Reproductive age (21-45) | Yes, with HSDD diagnosis | Contraception required; avoid in pregnancy | | Trying to conceive | No | Contraindicated; stop before TTC | | Pregnant | Never | Contraindicated; fetal harm in animals | | Breastfeeding | No | Unknown transfer; avoid | | Perimenopause | Not approved | Address hormonal causes first | | Postmenopause | Not approved | No trial data; not indicated |